USA flag logo/image

An Official Website of the United States Government

Reduction of Dietary Oxalate

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95846
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
AT006065
Solicitation Year:
N/A
Solicitation Topic Code:
NCCAM
Solicitation Number:
N/A
Small Business Information
CAPTOZYME, LLC
5745 SW 75TH ST, STE 298 GAINESVILLE, FL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Reduction of Dietary Oxalate
Agency: HHS
Contract: 1R43AT006065-01
Award Amount: $99,984.00
 

Abstract:

DESCRIPTION (provided by applicant): Kidney stones are a common and painful human health care problem worldwide. Of all stones developed approximately 70% are composed of calcium oxalate. Urinary oxalate is regarded as a driving force for calcium oxalate s tone formation, and absorption of dietary oxalate contributes to 10-70% of urinary oxalate. Treatment strategies that significantly reduce the absorption of dietary oxalate and subsequently decrease risk of stone formation are limited if not non-existent. The approach underlying this application is to find an oxalate-degrading enzyme from natural sources (edible fungi) with the ideal properties to be a potential therapeutic, medical food or dietary supplement: stable and active at pH 2.0-5.0, intracellular and/or associated with cell walls, and capable to degrade most available ingested oxalate in the human stomach within the gastric emptying time. This product will ideally be taken with meals and oxalate containing snacks. Such a product is likely to have a wide application within the calcium oxalate stone- forming population. PUBLIC HEALTH RELEVANCE: Kidney stones are a common and painful human health care problem. In Western countries including the United States, approximately 6-12% of the populatio n will develop kidney stones, and of all stones developed approximately 70% are primarily composed of calcium oxalate. Since there is currently no treatment strategy that is effective at degrading oxalate and subsequently reducing kidney stones, Captozyme is proposing to develop an oxalate-degrading enzyme that can effectively act as a dietary intercept and hence reduce the occurrence of calcium oxalate stone development.

Principal Investigator:

Qingshan Li

Business Contact:

Cowley
aaron.cowley@captozyme.com
Small Business Information at Submission:

CAPTOZYME, LLC
CAPTOZYME, LLC 5745 SW 75TH ST, STE 298 GAINESVILLE, FL 32608

EIN/Tax ID: 127032951
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No